Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Aggressive lymphoma subjects: diffuse large B cell lymphoma confirmed by immunohistochemistry and aaIPI≥3; double-hit lymphoma, as first-line or second-line consolidation therapy; peripheral T-cell lymphoma except ALK-positive type, as first-line or second-line consolidation therapy; mantle cell lymphoma, as first-line or second-line consolidation therapy.
Adequate organ system function including:
Creatinine clearance rate ≥ 80ml/min and creatinine < 160μmol/L ALT/AST ≤ 2 upper limit of normal Total Bilirubin < 2 upper limit of normal FEV1、FVC and DLCO ≥ 50% predictive value Left ventricular ejection fraction ≥ 50% No Symptomatic arrhythmia
Age 18-60 years, male and female
ECOG score 0-1
Number of neutrophil ≥ 1.5×10^9/L, number of platelet ≥ 70×10^9/L, concentration of hemoglobin ≥ 90g/L, number of CD34+ cells ≥ 2.0×10^6/kg
Expected survival ≥ 12 weeks
Volunteered to participate in this study and signed informed consent
Have evidence of CNS lymphoma
Relapse after autologous hematopoietic stem cell transplantation
Active hepatitis B or hepatitis C virus infection
Severe active infection
Liver cirrhosis or hepatic fibrosis
QTc > 500ms
Have mental disorder or unable to sign informed consent
History of drug abuse and intemperance
Women who are pregnant or lactating or have breeding intent
The investigators believe that any increase in the risk of the subject or interference with the results of the trial